What is Amniotics?
Founded in 2015, Amniotics operates at the intersection of biotechnology and advanced therapeutics, specializing in the isolation and cultivation of mesenchymal stem cells derived from amniotic fluid. By leveraging these unique biological resources, the company aims to address critical unmet needs in tissue repair and inflammatory disease management. Its strategic location in Sweden provides access to a robust ecosystem of life science innovation, allowing the firm to maintain a rigorous focus on high-quality, scalable cell-based therapies. As a specialized biopharma entity, Amniotics distinguishes itself through its commitment to ethical sourcing and the development of standardized, clinical-grade stem cell products that meet the stringent requirements of modern healthcare systems.
How much funding has Amniotics raised?
Amniotics has raised a total of $526K across 1 funding round:
Unspecified
$526K
Unspecified (2022): $526K with participation from Sandra Lindstedt and Vinnova
Key Investors in Amniotics
Vinnova
Vinnova is Sweden's innovation agency, dedicated to enhancing Swedish innovation capacity and competitiveness for sustainable growth through support for emerging technologies and health-related projects.
Sandra Lindstedt
An individual investor providing strategic capital to support the advancement of early-stage biopharmaceutical research and development.
What's next for Amniotics?
The recent influx of capital serves as a pivotal catalyst for Amniotics as it transitions into a more mature phase of enterprise-level operations. Moving forward, the company is expected to prioritize the expansion of its manufacturing capabilities and the acceleration of its clinical trial programs. By utilizing this financing to bolster its research infrastructure, Amniotics is poised to navigate the complexities of regulatory approval and market entry. The strategic focus will likely remain on scaling its proprietary platform to support broader therapeutic applications, thereby enhancing its long-term value proposition for stakeholders and patients alike. As the firm continues to refine its operational model, the integration of advanced bioprocessing techniques will be essential to maintaining its competitive edge in the global regenerative medicine market.
See full Amniotics company page
